期刊
EUROPEAN JOURNAL OF CANCER
卷 47, 期 14, 页码 2084-2090出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2011.06.014
关键词
Breast cancer; Neoadjuvant chemotherapy; Pathological complete response; Prognosis; Meta-analysis; Prognostic indicator
类别
资金
- Programme for New Century Excellent Talents in University
- Chinese Ministry of Education [108080]
- National Natural Science Foundation of China [30772133, 81072150]
- Independent Innovation Foundation of Shandong University (IIFSDU) [2009JQ007]
Neoadjuvant chemotherapy (NAC) has become a widely accepted method of sequencing systemic therapy for breast cancer treatment. While 'response to chemotherapy' in the neoadjuvant setting has been utilised to predict prognosis, the published data are inconsistent. The present meta-analysis was conducted to determine whether the pathologic response to NAC predicts for outcomes. Papers were selected from the PubMed database based on defined inclusion and exclusion criteria. Parameters such as number/percentage of patients having pCR and outcome statistics (i.e. overall survival (OS), disease-free survival (DFS), relapse-free survival (RFS)) were collected. The analysis included 16 studies with 3776 patients. The summary odds ratio (OR) estimating the association of OS with pCR was 3.44 (95% confidence interval [95%CI]: 2.45-4.84), with similar findings for DFS (OR = 3.41, 95%CI: 2.54-4.58) and RFS (OR = 2.45, 95%CI: 1.59-3.80). No obvious statistical heterogeneity was detected. Funnel plots and Egger's tests did not reveal publication bias. This meta-analysis confirms that pathologic response is a prognostic indicator for RFS, DFS and OS and suggests that patients achieving pCR after NAC have favourable outcomes. (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据